Skip to content
SPC Logo

MOVIPREP, powder for oral solution

Last Updated on eMC 07-Jul-2016 View document  | Norgine Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07-Jul-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 29-Apr-2016

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



 

Section 2 – minor change to the sentence regarding list of excipients.

 

Section 4.2 – addition of the word ‘clinical’ before procedure throughout various paragraphs.

 

Section 4.7 – minor amends to the wording of the sentence regarding ability to use machinery.

 

Section 4.8 – minor amendments to the description of the frequencies.

 

Section 5.3 – update to the information on reproductive toxicology studies.

Updated on 14-Aug-2015 and displayed until 07-Jul-2016

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Improved presentation of SPC

Date of revision of text on the SPC: 01-Jul-2015

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Please note the following changes to the  MOVIPREP SMPC

 

 

Section 2          -addition of the title – ‘Excipients with known affect’

 

Section 4.2       -an additional dosing option has been added to include the option of ‘two litres in the morning of the clinical procedure’. Further information around the dosing has been added.

                        -information around the method of administration has been added.

 

Section 4.3       -statement about the hypersensitivity to excipients has been aligned with QRD wording.

 

Section 4.4       -addition of the sentence ‘ The fluid content of Moviprep when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained’

                        -addition of statements regarding those at risk of arrhythmia

                        -addition of statements regarding the content of absorbable sodium, potassium and aspartame in relation to at risk patients.

 

Section 4.6       -general information added about use in pregnancy and breastfeeding.

 

Section 4.8       -the addition of the adverse event  arrhythmia, to cardiac disorders

                        -the order of some adverse events has been amended

                        -addition of the statement  ‘Dehydration may occur as a result of diarrhoea and/or vomiting.’

                        - addition of information regarding adverse event reporting.

 

Section 6.6       -information added to the precautions for disposal

 

Improved presentation of SPC

                        -the spelling of Sulphate has been changed from Sulphate and Sulfate throughout.

                        -MOVIPREP uppercase text has been changed to lowercase text throughout.

 

 

Updated on 24-Oct-2012 and displayed until 14-Aug-2015

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text

Date of revision of text on the SPC: 01-Jun-2012

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

In section 4.8 (undesirable effects), hypokalaemia has been added to investigations
In section 10 (date of revision of the text: chaged from 18/01/2011 to June 2012

Updated on 18-Nov-2011 and displayed until 24-Oct-2012

Reasons for adding or updating:

  • Change to section 1 -Name of the Medicinal product
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 10 date of revision of the text

Date of revision of text on the SPC: 18-Jan-2011

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:


Changes from the renewal of the marketing authorisation are to sections 1, 6.4, 10:
 
Section 1;

MOVIPREP, powder for oral solution - 'in sachets' has been removed
 
Section 6.4:

Sachets: Store below 25°C. ('Store in the original package' - has been removed).

Reconstituted Solution: Store below 25°C. The solution may be refrigerated. Keep the solution covered. 

 
Section 10: Date of revision of the text 18Jan2011

Updated on 25-Oct-2010 and displayed until 18-Nov-2011

Reasons for adding or updating:

  • Correction of spelling/typing errors

Date of revision of text on the SPC: 01-Jul-2010

Legal Category:P

Black Triangle (CHM): NO

Updated on 12-Oct-2010 and displayed until 25-Oct-2010

Reasons for adding or updating:

  • Introduction of new pack/pack size

Date of revision of text on the SPC: 06-Aug-2010

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Reason for revision – New SmPC / New PIL

 

Updated on 16-Aug-2010 and displayed until 12-Oct-2010

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data

Date of revision of text on the SPC: 01-Jul-2010

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

4.8 -

As with other macrogol containing products, allergic reactions including rash, urticaria, pruritus, angioedema and anaphylaxis are a possibility.

Data from clinical studies are available in a population of 825 patients treated with MOVIPREP in which undesirable effect data were actively elicited.  Additionally,  adverse events reported in postmarketing are included.

 

5.1

The physiological consequence is a propulsive colonic transportation of the softened stools.

The electrolytes present in the formulation and the supplementary clear liquid intake are included to prevent clinically significant variations of sodium, potassium or water, and thus reduce dehydration risk.



5.3

No studies have been carried out on the genotoxicity, carcinogenicity or toxic effect on reproduction with this product.

Updated on 28-Jul-2008 and displayed until 16-Aug-2010

Reasons for adding or updating:

  • Improved Electronic Presentation

Date of revision of text on the SPC: 27-Mar-2007

Legal Category:P

Black Triangle (CHM): NO

Updated on 17-Apr-2007 and displayed until 28-Jul-2008

Reasons for adding or updating:

  • Change to section 1 -Name of the Medicinal product
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text

Date of revision of text on the SPC: 01-Mar-2007

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

1.        Name of the medicinal product

 

           MOVIPREP, powder for oral solution in sachets

 

5.1       Pharmacodynamic properties

Macrogol 3350, sodium sulphate and high doses of ascorbic acid exert an osmotic action in the gut, which induce a laxative effect.  Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defaecation. The electrolytes present in the formulation as well as the supplementary clear liquid intake ensure that there are no clinically significant variations of sodium, potassium or water, and thus no dehydration risk.

 

5.2       Pharmacokinetic properties

Macrogol 3350 is unchanged along the gut.  It is virtually unabsorbed from the gastro-intestinal tract and has no known pharmacological activity.  Any macrogol 3350 that is absorbed is excreted via the urine

 

7.       MARKETING AUTHORISATION HOLDER

Norgine BV

Hogehilweg 7, 1101CA

Amsterdam ZO

The Netherlands

 

8.       MARKETING AUTHORISATION NUMBER(S)

PL: 20142/0005

10. DATE OF REVISION OF THE TEXT

 

27/03/2007.

Updated on 05-Jan-2007 and displayed until 17-Apr-2007

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 05-Jan-2007 and displayed until 05-Jan-2007

Reasons for adding or updating:

  • New SPC for new product

Company contact details

Norgine Limited

Company image
Address

Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS

Fax

+44 (0)1895 825 865

Medical Information e-mail
Telephone

+44 (0)1895 826 600

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulfate, anhydrous

Legal categories

P - Pharmacy

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue